Two men who received the Covishield vaccine trial shots at Bharati Vidyapeeth Medical College and Hospital on Wednesday are doing well with no side effects, senior officials of the concerned facility told on Thursday.
The two candidates, aged 32 and 48, were the first in India to be jabbed with the Oxford University and AstraZeneca COVID-19 vaccine manufactured in-country by Pune-based serum institute of India or SII.
The Serum Institute of India is the largest manufacturer of vaccines and biologics in the world, having sold over 1.5 billion doses of immunizations to 170 countries for Diptheria, R hepatitis b, measles, mumps, and rubella vaccines among others.
“Since yesterday our medical team is in touch with two volunteers and both are fine. They do not have any pain fever injection side reaction or systemic illness post-vaccination,” Dr. Jitendra Oswal, deputy medical director of Bharati Vidyapeeth Medical College told PTI.
Both the volunteers were jabbed with the Covishield vaccine and observed for 30-minutes and were allowed to return home. They’ll receive the second dose after 1 month.
Twenty-five candidates are in line to receive the vaccine in the next 7-days under India’s first clinical trial for the Oxford University developed coronavirus vaccine.
More than a hundred potential vaccine candidates are under the radar to bring the first WHO-approved and globally accepted vaccine for the novel coronavirus that have so far infected more than 22 million people globally.
The Serum Institute of India earlier announced they’ve partnered with Gavi, The Vaccine Alliance, and the Bill & Melinda Gates Foundation to accelerate the vaccine production and deliver up to 100 million doses of COVID-19 vaccine in 2021 for India and low- and middle-income countries (LMICs).